Dermatologist

Purpose

A dermatologist exists to read the largest organ of the body — the skin — as both a surface to be diagnosed and a window into what is happening beneath it. The skin shows everything: the benign mole and the melanoma that will kill in two years, the rash that is an annoyance and the rash that is the first sign of a lethal drug reaction, the lesion of a systemic disease declaring itself on the forearm before the patient feels sick. The dermatologist's reason for being is to look — closely, with trained eyes and a dermatoscope — and to know which of the hundred things on the differential is the one that must come off and go to pathology today, and which can be reassured and watched.

Core Mission

Recognize the lesion or eruption for what it is by pattern, decide what to biopsy and what to leave, and catch the skin cancer and the dangerous drug reaction early enough to change the outcome — without cutting into every benign mole.

Primary Responsibilities

The visible work is looking at skin; the actual work is pattern recognition under the constant threat of the missed melanoma. A dermatologist takes a focused history (onset, evolution, symptoms, drugs, sun exposure, family history), examines the whole skin surface including the scalp, nails, and mucosa, applies dermoscopy to magnify and structure the diagnosis, and decides whether a lesion needs biopsy, excision, monitoring, or nothing. They classify and treat inflammatory disease — psoriasis, eczema, acne, the autoimmune blistering disorders — often for years. They perform skin surgery, including Mohs for high-risk cancers, and read their own and the pathologist's slides in clinicopathologic correlation. Underneath it all is morphology: the precise description of what a lesion looks like, because the name follows the description.

Guiding Principles

• Describe before you diagnose. The morphology — macule, papule, plaque, vesicle, distribution, color, border — is the data. Name the lesion in the language of dermatology and the differential narrows itself.
• The dangerous diagnosis sets the threshold. Most lesions are benign, but the cost of missing one melanoma is a life. The whole discipline of biopsy thresholds is built around that asymmetry.
• Pattern recognition is fast; the discipline is the lesion that breaks the pattern. The "ugly duckling" mole that looks different from all the patient's others is more suspicious than any single ABCDE feature.
• Dermoscopy turns guessing into reading. The naked eye sees a brown spot; the dermatoscope sees pigment networks, streaks, and blue-white veils that separate nevus from melanoma.
• A rash plus fever, mucosal involvement, or skin pain is an emergency until excluded. SJS/TEN, DRESS, and necrotizing infection hide among benign eruptions and kill fast.
• Treat the disease over time, not the flare in the room. Psoriasis and eczema are chronic; the plan is a long-term regimen, not a one-visit cream.

Mental Models

• ABCDE and the ugly-duckling sign. Asymmetry, Border irregularity, Color variegation, Diameter over 6 mm, and Evolution flag the suspicious mole; the ugly duckling — the lesion that doesn't match the patient's other moles — catches the melanomas that don't fit ABCDE. Used together, not as a checklist.
• The two-step dermoscopy algorithm. First decide melanocytic or not; if melanocytic, apply pattern analysis (or a scoring method like the 7-point checklist) to separate benign from malignant. Structure replaces hunch.
• Reaction patterns. Inflammatory skin disease sorts into a limited set of histologic and clinical patterns — spongiotic (eczema), psoriasiform, lichenoid, vesiculobullous, granulomatous. Recognize the pattern and the differential collapses to a handful.
• Distribution as diagnosis. Where a rash is tells you what it is: extensor surfaces and scalp suggest psoriasis; flexural suggests atopic dermatitis; photodistributed points to a drug or lupus; dermatomal means zoster.
• The biopsy as the tiebreaker, chosen to fit the question. Shave for raised lesions, punch for inflammatory rashes and full-thickness sampling, excisional for suspected melanoma so the depth (Breslow) can be measured intact.
• Clinicopathologic correlation. The slide and the bedside are read together; a histology report that doesn't fit the clinical picture is a reason to call the pathologist, not to accept a wrong answer.

First Principles

• The skin has a finite vocabulary of responses; the same morphology recurs across very different causes.
• A pigmented lesion's danger is mostly its depth, and depth is invisible from the surface — which is why suspicious lesions are excised whole, not shaved.
• Most skin cancer is slow and curable if caught; melanoma is the exception that justifies the vigilance applied to all of it.
• A rash that hurts more than it itches, or peels, is more worrying than one that merely itches.
• You cannot diagnose what you don't undress to see; the lesion is on the part of the skin the patient didn't mention.

Questions Experts Constantly Ask

• Is this lesion changing, and is it the ugly duckling among this patient's others?
• Does this need to come off and go to pathology today, or can I photograph and reassess in three months?
• Which biopsy technique answers the question this lesion is asking?
• Is this rash a benign eruption or the start of SJS/TEN, DRESS, or a necrotizing infection?
• What is the distribution telling me, and have I examined the scalp, nails, mucosa, and soles?
• Is this skin finding the disease, or a window onto a systemic illness or drug?

Decision Frameworks

• Biopsy vs. monitor vs. reassure. Biopsy any lesion with melanoma features or unexplained change; monitor borderline lesions with dermoscopic photography and short-interval recheck; reassure the clearly benign. The threshold drops with risk factors (fair skin, many nevi, personal or family history).
• Excisional vs. partial biopsy for pigmented lesions. Suspected melanoma is excised with narrow margins to preserve Breslow depth and architecture; partial sampling can understage and mislead the surgeon and the patient.
• The drug-eruption danger triage. Any drug rash gets checked for the red flags — mucosal lesions, skin pain, blistering, facial edema, fever, eosinophilia, organ involvement. Red flags stop the drug and escalate; their absence allows a measured approach.
• Topical vs. systemic vs. biologic in inflammatory disease. Severity, body surface area, and quality-of-life impact ladder the patient from topicals to phototherapy to systemic agents to targeted biologics.

Workflow

1. History, focused. Onset, evolution, symptoms, prior treatments, drugs, sun and occupational exposure, family history of melanoma.
2. Full-skin examination. Whole surface in good light, including scalp, nails, mucosa, palms, soles, and intertriginous areas; total-body photography for the high-risk mole patient.
3. Dermoscopy. Magnify suspicious lesions; apply the two-step algorithm to sort melanocytic from non-melanocytic and benign from malignant.
4. Decide and sample. Choose biopsy technique to fit the lesion and the question; mark and document.
5. Correlate. Read the pathology against the clinical picture; reconcile any mismatch with the pathologist.
6. Treat and stage. Excise with appropriate margins, refer for sentinel node when indicated, start the inflammatory regimen, and set the surveillance interval.
7. Surveil. Schedule recurring skin checks; the second melanoma is common in the patient who had a first.

Common Tradeoffs

• Sensitivity vs. over-biopsy. Lowering the biopsy threshold catches more melanomas and scars more benign moles; the number-needed-to-biopsy is a real cost the dermatologist owns.
• Cosmesis vs. margin. Wider excision and Mohs maximize clearance; the face demands tissue preservation, so the technique is matched to site and risk.
• Aggressive systemic therapy vs. its toxicity. Biologics and immunosuppressants clear severe psoriasis and eczema but carry infection and malignancy risk.
• Treating the flare fast vs. steroid harm. Potent topical steroids work but thin skin and rebound; the long game limits them.
• Reassurance vs. surveillance. Telling the worried patient a mole is benign vs. photographing it for safety; both have costs in anxiety and follow-up.

Rules of Thumb

• The lesion the patient didn't point to is the one you must examine.
• A changing mole is suspicious regardless of how benign it looks today.
• If it doesn't fit a benign pattern and you're reaching to explain it away, biopsy it.
• A rash that involves the mucous membranes is dangerous until proven otherwise.
• Symmetric, well-demarcated, and stable is reassuring; asymmetric, ill-defined, and evolving is not.
• When the clinical and the dermoscopic disagree, the more worrying one wins — biopsy.
• Photograph the borderline lesion so the next visit has a baseline, not a memory.

Failure Modes

• Missing the amelanotic or acral melanoma. Anchoring on pigment and ABCDE misses the pink nodule and the melanoma on the sole or under a nail.
• Shaving a melanoma. Transecting the lesion destroys the depth measurement the surgeon and the prognosis depend on.
• Treating a drug eruption as benign when it was the prodrome of SJS/TEN or DRESS.
• Calling everything eczema. Lumping unexplained chronic rashes into "eczema" and missing cutaneous lymphoma or a systemic disease.
• Steroid dependence. Chasing flares with ever-stronger topicals instead of a disease-modifying plan.
• Diagnostic momentum on the referral label. Accepting the referring "fungal rash" without scraping for KOH and re-examining.

Anti-patterns

• Treating without describing — prescribing a cream for a "rash" never characterized morphologically.
• The partial biopsy of a pigmented lesion that understages a melanoma.
• Cryotherapy of an undiagnosed lesion that destroys a cancer's histology.
• Polypharmacy of topicals layered until the regimen itself causes irritation.
• Skipping the dermatoscope on a pigmented lesion and biopsying or dismissing on naked-eye gestalt alone.

Vocabulary

• Macule / papule / plaque / nodule — flat, small raised, large raised, and deep raised lesions; the primary morphology.
• ABCDE — the melanoma screening features: asymmetry, border, color, diameter, evolution.
• Dermoscopy — surface microscopy revealing sub-surface pigment and vascular structures.
• Breslow thickness — the depth of a melanoma in millimeters; the dominant prognostic factor.
• Mohs surgery — staged excision with same-day margin mapping for high-risk skin cancer.
• Spongiosis / acanthosis / parakeratosis — histologic patterns naming epidermal reactions.
• SJS / TEN / DRESS — severe, sometimes fatal drug reactions of the skin.
• Nikolsky sign — skin sloughing with lateral pressure, a marker of blistering disease.

Tools

• The dermatoscope — the defining instrument; magnification and polarized light that turn a brown spot into a readable structure.
• Total-body photography and mole-mapping — baseline imaging for high-risk patients to detect change over time.
• The biopsy kit (shave, punch, excisional) — the means of getting tissue to the pathologist.
• KOH prep and Wood's lamp — bedside tests for fungus and pigment/fluorescence.
• Cryotherapy, electrosurgery, and lasers — for destroying benign and pre-malignant lesions.
• The Mohs microsurgery setup — for margin-controlled excision of facial and recurrent cancers.

Collaboration

Dermatology is tightly coupled to pathology — so tightly that many dermatologists read their own slides, and the dermatopathologist is the partner who confirms the diagnosis behind the diagnosis. Clinicopathologic correlation is a two-way conversation, not a one-way report. The dermatologist works with the plastic surgeon and head-and-neck surgeon for large reconstructions after cancer excision, the medical oncologist for advanced melanoma now treated with immunotherapy, the rheumatologist for the cutaneous signs of systemic autoimmune disease, and the primary care physician who refers the lesion and manages the patient's other illness. The recurring friction is the referral label: the discipline is to re-examine and re-describe rather than inherit a prior diagnosis.

Ethics

Dermatology straddles medical necessity and cosmetic demand, and the line is where the ethics live. The honest dermatologist biopsies what needs biopsying and declines to sell cosmetic procedures dressed up as medical ones. The asymmetry of melanoma justifies vigilance, but over-biopsy and overdiagnosis of indolent lesions cause real harm — scars, anxiety, and cost — and the patient deserves an honest account of the trade. Access matters: skin cancer is curable when caught early, and the patient who can't get a timely skin check is the one who presents with a thick melanoma. Diagnoses in skin of color are missed when the training images were all on light skin; the duty is to know the patterns across all patients. And reassurance must be honest — never falsely calm a changing lesion to end the visit faster.

Scenarios

The "stable old mole" the patient mentions in passing. A 50-year-old comes in for acne and offhandedly says a back mole has been there for years. On full-skin exam it's the ugly duckling — darker and more irregular than his dozen other nevi. Dermoscopy shows an atypical pigment network with focal blue-white veil. ABCDE is only borderline, but the ugly-duckling sign and the dermoscopic structures override the reassuring history. The expert performs an excisional biopsy with narrow margins — not a shave — preserving Breslow depth. Pathology: melanoma in situ. The discipline that caught it was examining the skin he didn't come in for and trusting structure over story.

The morbilliform rash on day 10 of an antibiotic. A patient develops a widespread red rash a week and a half into amoxicillin. Most are benign drug eruptions. The expert checks the red flags: facial edema, fever to 38.8, tender skin, and a lab shows eosinophilia with a rising ALT. This is DRESS, not a simple exanthem. The decision is to stop the drug immediately, admit, monitor organ function, and start systemic steroids — treating it as the potentially fatal reaction it is rather than reassuring and continuing.

The chronic "eczema" that won't clear. A 60-year-old has had an itchy, scaly, patchy eruption for two years, called eczema and treated with steroids that never quite work. The expert resists the inherited label, notes the patches are well-demarcated and somewhat atrophic in sun-protected sites, and biopsies rather than re-prescribing. Histology shows an atypical lymphocytic infiltrate: early mycosis fungoides (cutaneous T-cell lymphoma). Refusing to keep calling an unexplained chronic rash "eczema" changed the diagnosis and the patient's path.

Related Occupations

A dermatologist is a physician who specialized in skin, so internal medicine and the diagnostic discipline of the physician are the foundation. The pathologist — specifically the dermatopathologist — is the indispensable partner who confirms the tissue diagnosis, making clinicopathologic correlation a daily conversation. The medical oncologist now co-manages advanced melanoma with immunotherapy. The surgeon and plastic surgeon reconstruct large defects after cancer excision. Radiologic technologists and radiologists stage deeper or metastatic disease. The registered nurse runs the skin-cancer surveillance clinic and the biologic infusion program.

References

• Fitzpatrick's Dermatology in General Medicine
• Dermatology — Bolognia, Schaffer & Cerroni
• Andrews' Diseases of the Skin
• Dermoscopy: The Essentials — Soyer, Argenziano, et al.
• AAD Clinical Guidelines